Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. (Q45983175)

18 December 2017

http://europepmc.org/abstract/MED/19496103

title

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. (English)

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

0 references

1 reference

1

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

author name string

Sara Jafari

2

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

Firoozeh Raisi

3

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

Abbas Ali Nasehi

4

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

Aboulfazl Ghoreishi

5

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

Bahman Salehi

6

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

Soodeh Mohebbi-Rasa

7

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

Maedeh Raznahan

8

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

Abbas Kamalipour

9

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

publication date

1 January 2009

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

published in

Depression and Anxiety

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

volume

26

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

issue

7

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

page(s)

607-611

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

cites work

CSF Prostaglandin Levels in Depressed and Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

Major depression: emerging therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

The future of depression psychopharmacology

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Treating depression to full remission.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Cytokines and the brain: implications for clinical psychiatry

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Increased level of salivary prostaglandins in patients with major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Reducing the burden of depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Pharmacology of antidepressants--characteristics of the ideal drug

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

COX-2 inhibition in schizophrenia and major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

A detailed examination of cytokine abnormalities in Major Depressive Disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20589

7 January 2021

Identifiers

DOI

10.1002/DA.20589

1 reference

18 December 2017

http://europepmc.org/abstract/MED/19496103

1 reference

18 December 2017